-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with atrial fibrillation and mechanical heart valve implantation require continuous anticoagulant therapy, mainly vitamin K antagonists, but due to invasive surgery, patients need to discontinue warfarin treatment
Recently, researchers investigated the safety and effectiveness of postoperative low molecular weight heparin (LMWH) bridging
The study was carried out in 10 clinical centers in Canada and India.
Thrombus myocardial infarction blood vessel
The incidence of major thromboembolism within 90 days was 1.
The incidence of major thromboembolism within 90 days was 1.
Studies have concluded that in patients with atrial fibrillation or mechanical heart valve implantation who interrupted warfarin anticoagulation therapy due to surgery, postoperative dalteparin sodium bridging has no significant effect on preventing the risk of major thrombosis
In patients with atrial fibrillation or mechanical heart valve implantation who discontinued warfarin anticoagulation therapy due to surgery, postoperative dalteparin sodium bridging has no significant effect on preventing the risk of major thrombosis
Original source:
Michael J Kovacs et al.
Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial.
Leave a message here
